

Kidney Disease

REFERENCES

- Andreotti, F., Burzotta, F., Mazza, A., Manzoli, A., Robinson, K., Maseri, A. Homocysteine and arterial occlusive disease: a concise review. *Cardiologia* 1999 Apr; 44(4): 341-5.
- Aukema, H.M., Housini, I., Rawling, J.M. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. *J. Am. Soc. Nephrol.* 1999 Feb; 10(2): 300-8.
- Bacallao, R.L., Carone, F.A. Recent advances in the understanding of polycystic kidney disease. *Curr. Opin. Nephrol. Hypertens.* 1997 Jul; 6(4): 377-83.
- Bagchi, D., Bagchi, M., Stohs, S.J., Das, D.K., Ray, S.D., Kuszynski, C.A., Joshi, S.S., Pruess, H.G. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology* 2000 Aug 7; 148(2-3): 187-97.
- Barak, A.J., Beckenhauer, H.C., Tuma, D.J. Betaine, ethanol, and the liver: a review. *Alcohol* 1996; 13: 395-8.
- Boldt, J., Brosch, C., Piper, S.N., Suttner, S. et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. *Crit. Care Med.* 2001 May; 29(5): 952-7.
- Bostom, A.G., Shemin, D., Lapane, K.L., Hume, A.L., Yoburn, D., Nadeau, M.R., Bendich, A., Selhub, J., Rosenberg, I.H. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. *Kidney Int.* 1996 Jan; 49(1): 147-52.
- Brkljacic, B. et al. Renal vascular resistance in autosomal dominant polycystic kidney disease. Evaluation with color Doppler ultrasound. *Acta Radiol.* 1997 Sep; 38(5): 840-6.
- Chambers, S.T. Betaines: their significance for bacteria and the renal tract. *Clin. Sci.* 1995; 88(1): 25-7.
- Chapman, A.B., Johnson, A.M., Ranguet, S., Hossack, K., Gabow, P., Schrier, R.W. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. *J. Am. Soc. Nephrol.* 1997 Aug; 8(8): 1292-7.
- Chauveau, P., Chadeaux, B., Coude, M., Aupetit, J., Kamoun, P., Jungers, P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. *Miner. Electrolyte Metab.* 1996; 22(1-3): 106-9.
- Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., Graham, I. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N. Engl. J. Med.* 1991 Apr 25; 324(17): 1149-55.
- Clermont, G., Lecour, S., Lahet, J., Siohan, P., Vergely, C., Chevet, D., Rifle, G., Rochette, L. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. *Cardiovasc. Res.* 2000 Aug 18; 47(3): 618-23.
- Dierkes, J. et al. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. *Clin. Nephrol.* 1999 Feb; 51(2): 108-15.
- Ettinger, B. et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. *J. Urol.* 1997 Dec; 158(6): 2069-73.
- Fored, C.M., Ejerblad, E., Lindblad, P., Fryzek, J.P., Dickman, P.W., Signorello, L.B., Lipworth, L., Elinder, C.G., Blot, W.J., McLaughlin, J.K., Zack, M.M., Nyren, O. Acetaminophen, aspirin, and chronic renal failure. *N. Engl. J. Med.* 2001 Dec 20; 345(25): 1801-8; comment, *N. Engl. J. Med.* 2001 Dec 20; 345(25): 1844-6.
- Franconi, F., Bennardini, F., Mattana, A. et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. *Am. J. Clin. Nutr.* 1995; 61: 1115-9.

Friedman, A.N., Bostom, A.G., Selhub, J., Levey, A.S., Rosenberg, I.H. The kidney and homocysteine metabolism. *J. Am. Soc. Nephrol.* 2001 Oct; 12(10): 2181-9.

Fukaya, H., Kanno, H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. *Nippon Jibinkoka Gakkai Kaiho* 1999 Jul; 102(7): 907-17 (in Japanese).

Gahl, W.A., Bernardini, I., Chen, S., Kurtz, D., Horvath, K. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. *J. Inherit. Metab. Dis.* 1988; 11: 291-8.

Glanze, W.D. *The Mosby Medical Encyclopedia, Revised Edition* 1996. St. Louis, MO: C.V. Mosby.

Grantham, J.J. Mechanisms of progression in autosomal dominant polycystic kidney disease. *Kidney Int. Suppl.* 1997 Dec; 63: S93-S97.

Grantham, J.J., Nair, V., Winklhofer, F. Cystic disease of the kidney. In Brenner & Rector's *The Kidney, Volume 2, Sixth Edition* 2000, pp. 1699-1730. Philadelphia, PA: W.B. Saunders.

Hahn, S. et al. Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. *J. Am. Soc. Nephrol.* 1998 Nov; 9(11): 2089-95.

Herrmann, W., Schorr, H., Geisel, J., Riegel, W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. *Clin. Chem. Lab. Med.* 2001 Aug; 39(8): 739-46.

Hoffer, L.J., Robitaille, L., Elian, K.M., Bank, I., Hongsprabhas, P., Mamer, O.A. Plasma reduced homocysteine concentrations are increased in end-stage renal disease. *Kidney Int.* 2001 Jan; 59(1): 372-7.

Joosten, E., Lesaffre, E., Riezler, R., Ghekiere, V., Dereymaeker, L., Pelemans, W., Dejaeger, E. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? *J. Gerontol. A Biol. Sci. Med. Sci.* 1997 Mar; 52(2): M76-M79.

Kalinowski, M. et al. Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis. *Pol. Merkuriusz. Lek.* 1999 Feb; 6(32): 76-8.

LaPorte, J. et al. Kidney stones. How to identify the cause and prevent recurrence. *Postgrad. Med.* 1990 Apr; 87(5): 219-23, 226.

Levin, A., Stevens, L., McCullough, P.A. Cardiovascular disease and the kidney: tracking a killer in chronic kidney disease. *Postgrad. Med.* 2002; 111(4): 53-60.

Licinio, J., Wong, M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. *Mol. Psychiatry* 1999 Jul; 4(4): 317-27.

Li Kam Wa, T.C. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. *Nephrol. Dial. Transplant.* 1997 Oct; 12(10): 2075-80.

Lingens, N., Freund, M., Seeman, T., Witte, K., Lemmer, B., Scharer, K. Circadian blood pressure changes in untreated children with kidney disease and conserved renal function. *Acta Paediatr.* 1997 Jul; 86(7): 719-23.

Marangon, K., O'Byrne, D., Devaraj, S., Jialal, I. Validation of an immunoassay for measurement of plasma total homocysteine. *Am. J. Clin. Pathol.* 1999 Dec; 112(6): 757-62.

McCaddon, A., Davies, G., Hudson, P., Tandy, S., Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. *Int. J. Geriatr. Psychiatry* 1998 Apr; 13(4): 235-9.

McCully, K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am. J. Pathol.* 1969 Jul; 56(1): 111-28.

McGregor, D., Shand, B., Lynn, K. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. *Nephron* 2000 Jul; 85(3): 215-20.

Merta, M., Stekrova, J., Zidovska, J., Vorsilkova, M., Walterova, J., Kapras, J., Alanova, M., Raskova, D., Gaillyova, R., Archmanova, E., Rysava, R. DNA diagnosis and clinical manifestations of autosomal dominant polycystic kidney disease. *Folia Biol.* 1997; 43(5): 201-4.

Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? *Emerg. Infect. Dis.* 1997 Apr-Jun; 3(2): 113-27.

Mukoyama, A., Ushijima, H., Nishimura, S., Koike, H., Toda, M., Hara, Y., Shimamura, T. Inhibition of rotavirus and enterovirus infections by tea extracts. *Jpn. J. Med. Sci. Biol.* 1991 Aug; 44(4): 181-6.

Naidu, M.U., Shifow, A.A., Kumar, K.V., Ratnaker, K.S. Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats. *Phytomedicine* 2000 Jun; 7(3): 191-7.

National Kidney Foundation. Millions of Americans May Be at Risk for Kidney Disease: Simple Blood Tests Can Detect Your Risk 2001a Feb 26. New York: National Kidney Foundation (www.kidney.org).

National Kidney Foundation. Nutrition and Chronic Kidney Disease 2001b. New York: National Kidney Foundation.

National Kidney Foundation. Phosphorous and Renal Diet 2001c. New York: National Kidney Foundation.

National Kidney Foundation. Potassium and Renal Diet 2001d. New York: National Kidney Foundation.

National Kidney Foundation. Vitamins and Minerals in Kidney Disease 2001e. New York: National Kidney Foundation.

National Kidney and Urologic Diseases Information Clearinghouse. What Are Kidney Stones? 1998. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse/ National Institute of Diabetes & Digestive & Kidney Diseases.

Navarro, J.F., Mora, C., Rivero, A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. *Am. J. Kidney Dis.* 1999a Mar; 33(3): 458-63.

Navarro, J.F., Mora, C., Garcia, J. et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. *Scand. J. Urol. Nephrol.* 1999b Apr; 33(2): 121-5.

NCHS. Current Estimates from the National Health Interview Survey, 1996. 1999 Oct, Series 10(200). Atlanta, GA: National Center for Health Statistics/Centers for Disease Control and Prevention/U.S. Department of Health and Human Services.

NIDDK. What Are Kidney Stones? 1998. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Kidney Diseases Dictionary Index 1999. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Anemia in Kidney Disease and Dialysis 2001a Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Kidney and Urologic Diseases Statistics for the United States 2001b Dec. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NORD. Renal Disease Overview 2002. Universal City, CA: National Organization for Renal Disease (www.stop-ersd.org).

Ogborn, M.R., Nitschmann, E., Weiler, H.A., Bankovic-Calic, N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. *Kidney Int.* 2000 Jan; 57(1): 159-66.

Ohgitani, S., Fujita, T. Calcium decreases urinary oxalate. *Nippon Ronen Igakkai Zasshi* 2000 Oct; 37(10): 805-10 (in Japanese).

Ranich, T., Bhathena, S.J., Velasquez, M.T. Protective effects of dietary phytoestrogens in chronic renal disease. *J. Ren. Nutr.* 2001 Oct; 11(4): 183-93.

Ray, S.D., Patel, D., Wong, V., Bagchi, D. In vivo protection of DNA damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636

grape seed proanthocyanidin extract. *Res. Commun. Mol. Pathol. Pharmacol.* 2000; 107(1-2): 137-66.

Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., Vigo, P., Mayer, E.L., Selhub, J., Kutner, M., Jacobsen, D.W. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. *Circulation* 1996 Dec 1; 94(11): 2743-8.

Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. *Urol. Int.* 1997; 58(2): 93-9.

Sadava, D., Luo, P.W., Casper, J. Induction of renal damage in rats by a diet deficient in antioxidants. *Nutr. Res.* 1996; 16(9): 1607-12.

Saionji, K. et al. Homeostasis of antioxidant status in hemodialysis patients. *Rinsho Byori* 1999 May; 47(5): 461-6 (in Japanese).

Sakurauchi, Y. et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. *Am. J. Kidney Dis.* 1998 Aug; 32(2): 258-64.

Selhub, J. Homocysteine metabolism. *Annu. Rev. Nutr.* 1999; 19: 217-46.

Selhub, J., Jacques, P.F., Bostom, A.G., D'Agostino, R.B., Wilson, P.W., Belanger, A.J., O'Leary, D.H., Wolf, P.A., Schaefer, E.J., Rosenberg, I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. *N. Engl. J. Med.* 1995 Feb 2; 332(5): 286-91.

Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W., Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N. Engl. J. Med.* 2002 Feb 14; 346(7): 476-83.

Sessa, A., Ghiggeri, G.M., Turco A.E. Autosomal dominant polycystic kidney disease: clinical and genetic aspects. *J. Nephrol.* 1997 Nov-Dec; 10(6): 295-310.

Sloan, R.S., Kastan, B., Rice, S.I., Sallee, C.W., Yuenger, N.J., Smith, B., Ward, R.A., Brier, M.E., Golper, T.A. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. *Am. J. Kidney Dis.* 1998 Aug; 32(2): 265-72; comment, *Am. J. Kidney Dis.* 1999 Aug; 34(2): 400-1.

Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V., Hennekens, C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. *JAMA* 1992 Aug 19; 268(7): 877-81.

Stampfer, M.J., Malinow, M.R. Can lowering homocysteine levels reduce cardiovascular risk? *N. Engl. J. Med.* 1995 Feb 2; 332(5): 328-9.

Suliman, M.E., Lindholm, B., Barany, P., Bergstrom, J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. *Clin. Chem. Lab. Med.* 2001 Aug; 39(8): 734-8.

Suresh Babu, P., Srinivasan, K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. *Mol. Cell. Biochem.* 1998 Apr; 181(1-2): 87-96.

Takei, K., Ito, H., Masai, M., Kotake, T. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. *Urol. Int.* 1998; 61(3): 192-5.

Tomobe, K., Philbrick, D.J., Ogborn, M.R., Takahashi, H., Holub, B.J. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. *Am. J. Kidney Dis.* 1998 Jan; 31(1): 55-61.

Trachtman, H., Sturman, J.A. Taurine: a therapeutic agent in experimental kidney disease. *Amino Acids* 1996; 11(1): 1-13.

Tucker, K.L., Mahnken, B., Wilson, P.W., Jacques, P., Selhub, J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. *JAMA* 1996 Dec 18; 276(23): 1879-85.

Ueland, P.M., Ulvik, R.J., Refsum, H. Routine determination of homocysteine in plasma. A new and improved possibility for risk evaluation and diagnosis of common diseases. *Tidsskr. Nor. Laegenforen.* 1992 Sep 30; 112(23): 2977-80 (in Norwegian).

Umegaki, K., Shinozuka, K., Watarai, K., Takenaka, H., Yoshimura, M., Daohua, P., Esashi, T. Gingo biloba extract attenuates the development of hypertension in dioxycorticosterone acetate-salt hypertensive rats. *Clin. Exp. Pharmacol. Physiol.* 2000 Apr; 27 (4): 277-82.

USRDS. USRDS 2001 Annual Data Report 2001 Nov 21. U.S. Renal Data System. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (www.usrds.org).

Van der Meide, P.H., Schellekens, H. Cytokines and the immune response. *Biotherapy* 1996; 8(3-4): 243-9.

van Guldener, C., Janssen, M.J., de Meer, K. et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. *J. Intern. Med.* 1999; 245: 175-83.

van Guldener, C., Stehouwer, CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. *Semin. Thromb. Hemost.* 2000; 26(3): 281-9.

Velasquez, M.T., Bhathena, S.J. Dietary phytoestrogens: a possible role in renal disease protection. *Am. J. Kidney Dis.* 2001 May; 37(5): 1056-68.

Venkatesan, N., Punithavathi, D., Arumugam, V. Curcumin prevents adriamycin nephrotoxicity in rats. *Br. J. Pharmacol.* 2000 Jan; 129(2): 231-4.

Verhoef, P., Stampfer, M.J., Buring, J.E., Gaziano, J.M., Allen, R.H., Stabler, S.P., Reynolds, R.D., Kok, F.J., Hennekens, C.H., Willett, W.C. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. *Am. J. Epidemiol.* 1996 May 1; 143(9): 845-59.

Walser, M. et al. Can renal replacement be deferred by a supplemented very low protein diet? *J. Am. Soc. Nephrol.* 1999 Jan; 10 (1): 110-6.

Wanic-Kossowska, M., Bombicki, K., Koziol, L., Czarnecki, R. Levels of L-carnitine in serum of patients with chronic renal failure treated by hemodialysis (HD). *Pol. Arch. Med. Wewn.* 1998 Apr; 99(4): 314-22.

Wardle, E.N. Antioxidants in the prevention of renal disease. *Renal Fail.* 1999 Nov; 21(6): 581-91.

Welch, G.N., Loscalzo, J. Homocysteine and atherothrombosis. *N. Engl. J. Med.* 1998 Apr 9; 338(15): 1042-50.

Wendel, U., Bremer, H.J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. *Eur. J. Pediatr.* 1984; 142: 147-50.

Wilcken, D.E.L., Wilcken, B., Dudman, N.P.B., Tyrrell, P.A. Homocystinuria?the effects of betaine in the treatment of patients not responsive to pyridoxine. *N. Engl. J. Med.* 1983; 309: 448-53.

Williams, C.P., Child, D.F., Hudson, P.R., Davies, G.K., Davies, M.G., John, R., Anandaram, P.S., De Bolla, A.R. Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study. *J. Clin. Pathol.* 2001 Jan; 54(1): 54-62.

Wratten, M.L. et al. Haemolipodialysis. *Blood Purif.* 1999; 17(2-3): 127-33.

Yokozawa, T., Chung, H.Y., He, L.Q., Oura, H. Effectiveness of green tea tannin on rats with chronic renal failure. *Biosci. Biotechnol. Biochem.* 1996 Jun; 60(6): 1000-5.

Yokozawa, T., Nakagawa, T., Lee, K.I., Cho, E.J., Terasawa, K., Takeuchi, S. Effects of green tea tannin on cisplatin-induced nephropathy in LLC-PK1 cells and rats. *J. Pharm. Pharmacol.* 1999 Nov; 51(11): 1325-31.

Yuan, C.F., Lin, C.Y., Chen, T.W., Yang, M.L., Ng, H.T. Linkage analysis of families with autosomal dominant polycystic kidney disease by KG8-CA marker. *Zhonghua Yi Xue Za Zhi* 1997 Sep; 60(3): 125-9.

disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.